← Back to patent-cliff list
利福布汀
Tier C — Watch / tradeRifabutin
辉瑞
Originator
1992
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：RNAP
Brand：Mycobutin、Ansatipin、Ansatipine
Indications (approved)：耐多药肺结核、鸟-胞内分枝杆菌复合群病
Regional status
US
批准上市
1992-12-23
EU
-
China
批准上市
2007-12-28
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Rifabutin?
Approved indications include: 耐多药肺结核, 鸟-胞内分枝杆菌复合群病.
When does the Rifabutin patent expire?
No public expiry year is available for Rifabutin yet; this page updates once verified.
How do I get a quote for Rifabutin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25